Allarity Therapeutics: president and chief development officer Jeremy Graff exercised 87,641 shares

What happened

• Jeremy Graff, president and chief development officer, exercised or converted restricted stock units into 48,147 shares on Jan 22, 2026 and 39,494 shares on Sep 30, 2026, a total of 87,641 shares.
• The company withheld 17,814 shares on Jan 22, 2026 at $1.18 for $21,021 and 14,613 shares on Sep 30, 2026 at $0.97 for $14,175 to satisfy tax withholding obligations.

Key details

• Transaction dates and amounts: Jan 22, 2026 converted 48,147 RSUs; Jan 22, 2026 withholding 17,814 shares at $1.18 for $21,021. Sep 30, 2026 converted 39,494 RSUs; Sep 30, 2026 withholding 14,613 shares at $0.97 for $14,175.
• Shares owned after the reported transactions: the filing states 55,214 shares of common stock and 308,616 unvested restricted stock units outstanding (per footnote correction).
• Relevant footnotes: F1 (RSUs convert one-for-one), F2 (grant and vesting schedules), F3 (shares withheld to satisfy tax withholding), F4 and F5 (explanation of RSU balances and correction to prior report).
• Filing date and timeliness: Form 4 was filed Oct 9, 2026; the reported transactions on Jan 22, 2026 and Sep 30, 2026 were filed late.

Why it may matter

• The filing shows RSUs converted to common stock and that shares were withheld to cover tax obligations, a cashless withholding rather than an open-market sale of those withheld shares.
• The filing does not show why the insider traded or why the company acted.